HOOKIPA PHARMA INC. Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
HOOKIPA PHARMA INC. had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $1.43 million as of 2024-12-31, per its 10-K filed 2025-02-28.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2025-02-28
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.43M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.42M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.25M.
- 2021-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $1.21M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2024-12-31 | $1.43M 10-K · filed 2025-02-28 |
| 2023-12-31 | $1.42M 10-K · filed 2025-02-28 |
| 2022-12-31 | $1.25M 10-K · filed 2024-03-22 |
| 2021-12-31 | $1.21M 10-K · filed 2023-03-15 |
| 2020-12-31 | $2.73M 10-K · filed 2022-03-24 |
| 2019-12-31 | $2.72M 10-K · filed 2021-03-18 |
| 2018-12-31 | $51.00K 10-K · filed 2020-03-19 |